Deadline: 21-Aug-2025
Pfizer is inviting proposals for educational initiatives that address the burden of COVID-19 among adult patients with high-risk conditions. These programs are intended for geriatricians, infectious disease specialists, and primary care providers who manage such patients. The goal is to improve their ability to identify, diagnose, and manage COVID-19 effectively, particularly in communities where awareness is low and there is hesitancy toward oral treatments.
COVID-19 continues to pose a serious health threat, especially for high-risk groups who experience higher rates of hospitalization and mortality. Pfizer seeks to support programs that educate healthcare professionals (HCPs) about identifying patients at risk of severe outcomes, emphasizing the importance of early treatment, understanding complications related to high-risk conditions, and recognizing long-term effects such as long COVID and related diseases like diabetes or cardiovascular disorders.
Projects that use web-based platforms capable of reaching HCPs across multiple countries and supporting multiple languages will be considered. Each project may request up to $175,000 in funding, with higher budgets evaluated on a case-by-case basis. The maximum duration for each project is one year.
Eligible applicants include medical, dental, nursing, allied health, and pharmacy schools, healthcare institutions, professional societies, and education companies. Only organizations can apply, not individuals or independent medical practice groups. If the proposal involves multiple institutions, all must play a relevant role, and the main applicant must lead the project or be an authorized representative.
The project lead must be an employee or contractor of the applying organization, which must be able to legally receive funds directly from Pfizer. For programs that offer continuing education credits, the applicant must also be an accredited provider. The initiative is global in scope, excluding the U.S., with a priority focus on Europe and the Asia-Pacific region.
For more information, visit Pfizer.
